相关实验视频

Updated: Jun 28, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

GSK0660通过减少PD-L1表达来增强抗瘤免疫疗法

Bibimaryam Khan¹, Mingjun Chen², Huijie Wang²

¹School of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu Province, 212013, China; School of Medicine, Jiangsu University, Zhenjiang, Jiangsu Province, 212013, China.

European journal of pharmacology

|April 10, 2024

概括

当与PD-1阻断结合时,PPARδ对手GSK0660减少了结肠癌细胞中的PD-L1表达,增强了T细胞活性并改善了结肠直肠癌免疫疗法.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

PD-1/PD-L1免疫检查点阻断是癌症治疗的关键,但患者的反应率仍然很低.
在瘤免疫逃逸中,氧酶增殖器激活受体三角体 (PPARδ) 的作用尚不清楚.
PPARδ影响细胞增殖,炎症和瘤进展.

研究的目的:

研究PPARδ对结肠癌中PD-L1表达的作用.
评估PPARδ对抗的潜力,作为一种增强癌症免疫疗法的策略.

主要方法:

在结肠癌细胞系中利用GSK0660,一种PPARδ抗剂.
通过各种测试评估PD-L1蛋白和基因表达.
进行了 luciferase 记者测定,以分析基因转录活动.
在植入瘤模型中评估T细胞活动和瘤免疫逃逸.

主要成果:

GSK0660显著降低了结肠癌细胞中的PD-L1蛋白和基因表达.
GSK0660以PPARδ-依赖的方式降低了PD-L1基因转录活性.
减少PD-L1表达导致T细胞活性增加,并抑制瘤免疫逃生.
结合治疗GSK0660和PD-1抗体增强结直肠癌免疫疗法.

结论:

特别是与GSK0660的PPARδ对抗作用,有效地降低了结肠癌中PD-L1的表达.
GSK0660在克服癌症中的免疫逃生机制方面表现有前途.
结合GSK0660和PD-1封锁代表了改善结直肠癌免疫治疗结果的潜在策略.

关键词:

大肠癌是什么意思大肠癌是什么意思在GSK066060中使用.免疫逃脱是为了逃脱免疫.免疫治疗是一种免疫疗法.在PD-L1中.转录转录转录转录

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.